Here, we observe that p16Ink4a-overexpressing sarcoma cells are resistant to small molecules shown to be toxic against p16Ink4a +-senescent cells, but are sensitive to a novel suicide gene therapy regulated by the full p16Ink4a promoter. This evidence concerns the gene CDKN2A and sarcoma.